{"id":40836,"date":"2026-09-17T15:01:44","date_gmt":"2026-09-17T13:01:44","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/?p=40836"},"modified":"2026-09-08T13:29:34","modified_gmt":"2026-09-08T11:29:34","slug":"der-dritte-fcrn-modulator-zur-therapie-der-myasthenia-gravis-fortschritt-oder-scheininnovation","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2026\/der-dritte-fcrn-modulator-zur-therapie-der-myasthenia-gravis-fortschritt-oder-scheininnovation","title":{"rendered":"Der dritte FcRn-Modulator zur Therapie der Myasthenia gravis: Fortschritt oder Scheininnovation?"},"content":{"rendered":"<p>IgG-Autoantik\u00f6rper sind die zugrundeliegende pathogenetische Ursache f\u00fcr die generalisierte Myasthenia gravis (gMG), da sie die neuromuskul\u00e4re \u00dcbertragung durch Bindung an den Acetylcholinrezeptor (AChR), die muskelspezifische Tyrosinkinase (MuSK) oder das Lipoproteinrezeptor-verwandte Protein\u00a04 (LRP4) beeintr\u00e4chtigen . Etwa 95% der Patienten mit gMG sind antik\u00f6rperpositiv: 85% gegen AChR, etwa 8% gegen MuSK und etwa 1-2% gegen das LRP4 [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>IgG-Autoantik\u00f6rper sind die zugrundeliegende pathogenetische Ursache f\u00fcr die generalisierte Myasthenia gravis (gMG), da sie die neuromuskul\u00e4re \u00dcbertragung durch Bindung an den Acetylcholinrezeptor (AChR), die muskelspezifische Tyrosinkinase (MuSK) oder das Lipoproteinrezeptor-verwandte Protein\u00a04 (LRP4) beeintr\u00e4chtigen . Etwa 95% der Patienten mit gMG sind antik\u00f6rperpositiv: 85% gegen AChR, etwa 8% gegen MuSK und etwa 1-2% gegen das LRP4 [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[2946,6435,6432,6433,6436,6437,6434,6438],"class_list":["post-40836","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-eculizumab","tag-efgartigimod-alfa","tag-myasthenia-gravis","tag-nipocalimab","tag-ravulizumab","tag-rozanolixizumab","tag-vivacity-mg3-studie","tag-zilucoplan"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/40836","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=40836"}],"version-history":[{"count":3,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/40836\/revisions"}],"predecessor-version":[{"id":40839,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/40836\/revisions\/40839"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=40836"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=40836"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=40836"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}